Literature DB >> 21228923

Enhanced expression of CD74 in gastrointestinal cancers and benign tissues.

David V Gold1, Rhona Stein, Jack Burton, David M Goldenberg.   

Abstract

CD74, a transmembrane glycoprotein that associates with MHC II, is an important chaperone that regulates antigen presentation for immune response. In addition, CD74 is the receptor for macrophage migration-inhibitory factor which, when bound to CD74, initiates survival pathways and cell proliferation. Formalin fixed, paraffin embedded clinical specimens were evaluated by immunohistochemical procedures for expression of CD74. Overall, expression of CD74 within gastrointestinal carcinomas showed a statistically greater expression than in the normal tissue counterparts (P<0.001 or better). CD74 expression was observed in 95% of pancreatic carcinomas with the majority of cases presenting a mostly intense, diffuse labeling pattern. The results suggested a trend towards greater expression within the higher grade carcinomas (P=0.06). Colorectal and gastric carcinomas gave similar results with 60% and 86%, respectively, positive for CD74 with an intense, diffuse staining pattern. We hypothesized that precursor lesions would express levels of CD74 as high, or higher, than their respective carcinomas, since activation of survival pathways would be of particular importance at the early stages of neoplastic development. For PanIN lesions there was greater expression of CD74 within higher grade, PanIN-3 lesions, whereas the colonic adenomas showed no such trend, but overall, a higher frequency and intensity of CD74 labeling than was observed within the colon carcinomas. These findings are supportive of a role for CD74 in the development and maintenance of gastrointestinal neo-plasia, and provide a rationale for development of therapeutic agents that are able to block CD74 function, specifically within the tumor cell.

Entities:  

Keywords:  CD74; colon carcinoma; gastric carcinoma; invariant chain; pancreatic carcinoma

Mesh:

Substances:

Year:  2010        PMID: 21228923      PMCID: PMC3016099     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  37 in total

1.  Establishment of perineural invasion models and analysis of gene expression revealed an invariant chain (CD74) as a possible molecule involved in perineural invasion in pancreatic cancer.

Authors:  Norimasa Koide; Taketo Yamada; Rie Shibata; Taisuke Mori; Mariko Fukuma; Ken Yamazaki; Koichi Aiura; Motohide Shimazu; Setsuo Hirohashi; Yuji Nimura; Michiie Sakamoto
Journal:  Clin Cancer Res       Date:  2006-04-15       Impact factor: 12.531

2.  Polarized expression of CD74 by gastric epithelial cells.

Authors:  Carlos A Barrera; Ellen J Beswick; Johanna C Sierra; David Bland; Rosario Espejo; Randy Mifflin; Patrick Adegboyega; Sheila E Crowe; Peter B Ernst; Victor E Reyes
Journal:  J Histochem Cytochem       Date:  2005-05-27       Impact factor: 2.479

3.  Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines.

Authors:  G L Ong; D M Goldenberg; H J Hansen; M J Mattes
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

4.  cDNA clone for the human invariant gamma chain of class II histocompatibility antigens and its implications for the protein structure.

Authors:  L Claesson; D Larhammar; L Rask; P A Peterson
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

5.  CD74 is a survival receptor on colon epithelial cells.

Authors:  Nitsan Maharshak; Sivan Cohen; Frida Lantner; Gili Hart; Lin Leng; Richard Bucala; Idit Shachar
Journal:  World J Gastroenterol       Date:  2010-07-14       Impact factor: 5.742

6.  Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.

Authors:  Rhona Stein; Mitchell R Smith; Susan Chen; Maria Zalath; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

7.  Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival.

Authors:  Diana Starlets; Yael Gore; Inbal Binsky; Michal Haran; Nurit Harpaz; Lev Shvidel; Shirly Becker-Herman; Alain Berrebi; Idit Shachar
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

8.  Differential CD74 (major histocompatibility complex Class II invariant chain) expression in mouse and human intestinal adenomas.

Authors:  R J Cuthbert; J M Wilson; N Scott; P L Coletta; M A Hull
Journal:  Eur J Cancer       Date:  2009-03-09       Impact factor: 9.162

9.  Lymphoid monoclonal antibodies reactive with lung tumors. Diagnostic applications.

Authors:  H L Ioachim; S E Pambuccian; M Hekimgil; F R Giancotti; B H Dorsett
Journal:  Am J Surg Pathol       Date:  1996-01       Impact factor: 6.394

10.  Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype.

Authors:  Xueqing Lu; Nikoletta L Kallinteris; Jizhi Li; Shuzhen Wu; Yu Li; Zhong Jiang; Gilda G Hillman; Joseph V Gulfo; Robert E Humphreys; Minzhen Xu
Journal:  Cancer Immunol Immunother       Date:  2003-06-19       Impact factor: 6.968

View more
  10 in total

Review 1.  Mobile elements and viral integrations prompt considerations for bacterial DNA integration as a novel carcinogen.

Authors:  Kelly M Robinson; Julie C Dunning Hotopp
Journal:  Cancer Lett       Date:  2014-06-21       Impact factor: 8.679

2.  Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas.

Authors:  Peter Martin; Richard R Furman; Sarah Rutherford; Jia Ruan; Scott Ely; June Greenberg; Morton Coleman; Stanley J Goldsmith; John P Leonard
Journal:  Leuk Lymphoma       Date:  2015-05-12

3.  Metastatic Transition of Pancreatic Ductal Cell Adenocarcinoma Is Accompanied by the Emergence of Pro-Invasive Cancer-Associated Fibroblasts.

Authors:  Shaofei Liu; Yasir Suhail; Ashkan Novin; Lorrie Perpetua
Journal:  Cancers (Basel)       Date:  2022-04-28       Impact factor: 6.575

4.  Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells.

Authors:  Xinbo Wang; Jiaying Miao; Sizhen Wang; Rongxi Shen; Shuo Zhang; Yurao Tian; Min Li; Daojun Zhu; Anlong Yao; Wei Bao; Qun Zhang; Xingming Tang; Xingyun Wang; Jieshou Li
Journal:  Mol Cancer       Date:  2022-06-22       Impact factor: 41.444

5.  CD74-dependent deregulation of the tumor suppressor scribble in human epithelial and breast cancer cells.

Authors:  Gergana Metodieva; Naiara Correa Nogueira-de-Souza; Christina Greenwood; Khalid Al-Janabi; Lin Leng; Richard Bucala; Metodi V Metodiev
Journal:  Neoplasia       Date:  2013-06       Impact factor: 5.715

6.  Immunophenotyping of the cluster of differentiation 74, migration inhibitory factor, and cluster of differentiation 44 expression on human breast cancer-derived cell lines.

Authors:  Hussain Al Ssadh; Waleed Al Abdulmonem
Journal:  Int J Health Sci (Qassim)       Date:  2019 Mar-Apr

7.  CD74 and HLA-DRA in Cervical Carcinogenesis: Potential Targets for Antitumour Therapy.

Authors:  Carol K Balakrishnan; Gee Jun Tye; Shandra Devi Balasubramaniam; Gurjeet Kaur
Journal:  Medicina (Kaunas)       Date:  2022-01-26       Impact factor: 2.430

8.  Bacteria-human somatic cell lateral gene transfer is enriched in cancer samples.

Authors:  David R Riley; Karsten B Sieber; Kelly M Robinson; James Robert White; Ashwinkumar Ganesan; Syrus Nourbakhsh; Julie C Dunning Hotopp
Journal:  PLoS Comput Biol       Date:  2013-06-20       Impact factor: 4.475

9.  Measurements of heterotypic associations between cluster of differentiation CD74 and CD44 in human breast cancer-derived cells.

Authors:  Hussain Al Ssadh; Patrick S Spencer; Waleed Alabdulmenaim; Rana Alghamdi; Inamul Hasan Madar; Jose M Miranda-Sayago; Nelson Fernández
Journal:  Oncotarget       Date:  2017-09-14

10.  CD74 interacts with CD44 and enhances tumorigenesis and metastasis via RHOA-mediated cofilin phosphorylation in human breast cancer cells.

Authors:  Zhiyong Liu; Shuzhou Chu; Shun Yao; Yu Li; Songqing Fan; Xiaoyang Sun; Ling Su; Xiangguo Liu
Journal:  Oncotarget       Date:  2016-10-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.